Powered by: Motilal Oswal

News

Granules India shines on getting nod from Brazilian Health Regulatory Agency Granules India is currently trading at Rs. 299.85, up by 5.05 points or 1.71% from its previous closing of Rs. 294.80 on the BSE. The scrip opened at Rs. 296.85 and has touched a high and low of Rs. 300.60 and Rs. 295.20 respectively. So far 3035 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 267.85 on 29-Mar-2023. Last one week high and low of the scrip stood at R...
Granules India shines on getting nod from Brazilian Health Regulatory Agency
Granules India shines on getting nod from Brazilian Health Regulatory Agency
Source: Accord Fintech
25/08/2023 10:13:56 AM
Granules India trades in green on the BSE Granules India is currently trading at Rs. 325.40, up by 2.55 points or 0.79% from its previous closing of Rs. 322.85 on the BSE. The scrip opened at Rs. 325.00 and has touched a high and low of Rs. 327.30 and Rs. 323.90 respectively. So far 20269 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 267.85 on 29-Mar-2023. Last one week high and low of the scrip stood at ...
Granules India trades in green on the BSE
Granules India trades in green on the BSE
Source: Accord Fintech
9/08/2023 10:08:08 AM
Granules India rises on getting USFDA`s nod for Metoprolol Succinate ER Tablets Granules India is currently trading at Rs. 324.25, up by 3.80 points or 1.19% from its previous closing of Rs. 320.45 on the BSE. The scrip opened at Rs. 321.75 and has touched a high and low of Rs. 324.75 and Rs. 320.05 respectively. So far 43273 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 267.85 on 29-Mar-2023. Last one week high and low of the scrip stood at ...
Granules India rises on getting USFDA`s nod for Metoprolol Succinate ER Tablets
Granules India rises on getting USFDA`s nod for Metoprolol Succinate ER Tablets
Source: Accord Fintech
8/08/2023 2:55:26 PM
Avantel moves up on receiving Purchase Order worth of Rs 4.24 crore Granules India is currently trading at Rs. 303.95, up by 1.60 points or 0.53% from its previous closing of Rs. 302.35 on the BSE. The scrip opened at Rs. 305.00 and has touched a high and low of Rs. 305.75 and Rs. 302.25 respectively. So far 24057 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 267.85 on 29-Mar-2023. Last one week high and low of the scrip stood at ...
Avantel moves up on receiving Purchase Order worth of Rs 4.24 crore
Avantel moves up on receiving Purchase Order worth of Rs 4.24 crore
Source: Accord Fintech
14/07/2023 10:19:37 AM
Buy Granules India Ltd For Target Rs.350 - Motilal Oswal Improved business trajectory fueled by US ANDA approvals * After a lull of ANDA approvals in FY22/FY23, the pace of ANDA approvals has picked up for GRAN. * The company has already received 3 ANDA approvals in FY24 till date (vs. 4 in FY23). It is optimistic about receiving additional approvals in the remaining period of FY24. * Also, the recent approvals include certain limited competition products and/or certain products, where GRAN has a competitive edge over its peers in the manu...
Buy Granules India Ltd For Target Rs.350 - Motilal Oswal
Buy Granules India Ltd For Target Rs.350 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
7/07/2023 12:34:13 PM
Granules India gains after USFDA completes surveillance inspection at Jeedimetla facility with zero observations Granules India is currently trading at Rs. 288.75, up by 1.20 points or 0.42% from its previous closing of Rs. 287.55 on the BSE. The scrip opened at Rs. 287.55 and has touched a high and low of Rs. 290.50 and Rs. 281.40 respectively. So far 56630 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 238.05 on 23-Jun-2022. Last one week high and low of the scrip stood at ...
Granules India gains after USFDA completes surveillance inspection at Jeedimetla facility with zero observations
Granules India gains after USFDA completes surveillance inspection at Jeedimetla facility with zero observations
Source: Accord Fintech
23/06/2023 4:10:36 PM
Granules India gains on getting USFDA`s approval for Levetiracetam Tablets Granules India is currently trading at Rs. 288.30, up by 2.75 points or 0.96% from its previous closing of Rs. 285.55 on the BSE. The scrip opened at Rs. 285.75 and has touched a high and low of Rs. 289.00 and Rs. 285.75 respectively. So far 38097 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022. Last one week high and low of the scrip stood at ...
Granules India gains on getting USFDA`s approval for Levetiracetam Tablets
Granules India gains on getting USFDA`s approval for Levetiracetam Tablets
Source: Accord Fintech
14/06/2023 11:36:21 AM
Small Cap Buy Granules India Ltd For Target Rs. 342 - Geojit Financial Services Robust revenues across major markets Granules India Ltd. (Inc.) is a vertically integrated, high growth pharmaceutical company headquartered in Hyderabad, India. The company manufactures Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI) and Finished Dosages (FD). * Driven by higher sales in the USA and Europe, FY23 revenue grew by 20% YoY to Rs. 4,512 cr, despite the continued price erosion in the US market. * EBITDA climbed 27% YoY to Rs.914 cr,...
Small Cap Buy Granules India Ltd For Target Rs. 342 - Geojit Financial Services
Small Cap Buy Granules India Ltd For Target Rs. 342 - Geojit Financial Services
Source: Geojit Financial Services Ltd
13/06/2023 3:13:39 PM
Granules India jumps on getting USFDA`s approval for Metoprolol Succinate ER Tablets Granules India is currently trading at Rs. 284.45, up by 5.20 points or 1.86% from its previous closing of Rs. 279.25 on the BSE. The scrip opened at Rs. 280.50 and has touched a high and low of Rs. 285.00 and Rs. 279.70 respectively. So far 18691 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022. Last one week high and low of the scrip stood at ...
Granules India jumps on getting USFDA`s approval for Metoprolol Succinate ER Tablets
Granules India jumps on getting USFDA`s approval for Metoprolol Succinate ER Tablets
Source: Accord Fintech
13/06/2023 12:22:12 PM
Granules India rises on getting USFDA`s approval for Venlafaxine Hydrochloride Capsules Granules India is currently trading at Rs. 278.85, up by 1.20 points or 0.43% from its previous closing of Rs. 277.65 on the BSE. The scrip opened at Rs. 278.70 and has touched a high and low of Rs. 283.00 and Rs. 274.25 respectively. So far 26185 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022. Last one week high and low of the scrip stood at ...
Granules India rises on getting USFDA`s approval for Venlafaxine Hydrochloride Capsules
Granules India rises on getting USFDA`s approval for Venlafaxine Hydrochloride Capsules
Source: Accord Fintech
19/05/2023 11:37:08 AM
Granules India`s profit boosted by drug ingredient making business Granules India reported a 7.8% rise in fourth-quarter profit, spurred by strong growth in its business of making active pharmaceutical ingredient (API) for drugs. The company's consolidated net profit rose to 1.20 billion rupees ($14.7 million) in the quarter ended March 31, from 1.11 billion rupees a year earlier. Granules's consolidated revenue from operations rose 16% to 11.96 billion rupees, but a 17% jump in its total expenses ate into the profit growth. The company'...
Granules India`s profit boosted by drug ingredient making business
Granules India`s profit boosted by drug ingredient making business
Source: Reuters
16/05/2023 5:51:59 PM
Stock Picks : Granules India and PowerGrid (POWGRI) By ICICI Direct Granules India Granules India CMP 270.95; Stop Loss 275.60; Target 268.70   PowerGrid (POWGRI)  PowerGrid (POWGRI) CMP 222.10; Stop Loss 219.30; Target 224.80     To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631   Above views are of the author and not of...
Stock Picks : Granules India and PowerGrid (POWGRI) By ICICI Direct
Stock Picks : Granules India and PowerGrid (POWGRI) By ICICI Direct
Source: ICICI Direct
29/03/2023 10:19:23 AM
Granules India gains on getting USFDA`s nod for Gabapentin Tablets Granules India is currently trading at Rs. 272.00, up by 1.00 points or 0.37% from its previous closing of Rs. 271.00 on the BSE. The scrip opened at Rs. 269.00 and has touched a high and low of Rs. 272.80 and Rs. 267.85 respectively. So far 9195 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022. Last one week high and low of the scrip stood at R...
Granules India gains on getting USFDA`s nod for Gabapentin Tablets
Granules India gains on getting USFDA`s nod for Gabapentin Tablets
Source: Accord Fintech
29/03/2023 10:00:45 AM
Buy Granules India Ltd For Target Rs.370 - Anand Rathi Shares and Stock Brokers Broadly in-line Q3; attractive valuations currently; upgrading to a Buy Driven by good API sales (paracetamol), Granules India reported healthy Rs11.5bn Q3 revenue (up 15% y/y). More sales of low-margin paracetamol API led to the gross margin shrinking 140bps q/q. With most expenses continuing sequentially, the EBITDA margin contracted 93bps to 20.2%. Higher interest and depreciation costs led to net profit growing only 23% y/y to Rs1.3bn. Market-share gains and growth are expected from th...
Buy Granules India Ltd For Target Rs.370 - Anand Rathi Shares and Stock Brokers
Buy Granules India Ltd For Target Rs.370 - Anand Rathi Shares and Stock Brokers
Source: Anand Rathi Shares and Stock Brokers
24/02/2023 12:49:37 PM
Granules India gains as its arm receives ANDA approval for Amphetamine Mixed Salts ER Capsules Granules India is currently trading at Rs. 313.30, up by 1.20 points or 0.38% from its previous closing of Rs. 312.10 on the BSE. The scrip opened at Rs. 312.60 and has touched a high and low of Rs. 314.70 and Rs. 311.00 respectively. So far 5821 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022. Last one week high and low of the scrip stood at R...
Granules India gains as its arm receives ANDA approval for Amphetamine Mixed Salts ER Capsules
Granules India gains as its arm receives ANDA approval for Amphetamine Mixed Salts ER Capsules
Source: Accord Fintech
24/01/2023 10:48:38 AM
Granules India shines on entering into strategic partnership with Greenko ZeroC Granules India is currently trading at Rs. 329.30, up by 8.95 points or 2.79% from its previous closing of Rs. 320.35 on the BSE. The scrip opened at Rs. 322.70 and has touched a high and low of Rs. 329.35 and Rs. 322.00 respectively. So far 9504 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022. Last one week high and low of the scrip stood at R...
Granules India shines on entering into strategic partnership with Greenko ZeroC
Granules India shines on entering into strategic partnership with Greenko ZeroC
Source: Accord Fintech
3/01/2023 9:49:51 AM
Fredun Pharmaceuticals soars on bagging two contracts for Pharma and DC Granules Fredun Pharmaceuticals is currently trading at Rs. 1330.00, up by 49.95 points or 3.90% from its previous closing of Rs. 1280.05 on the BSE. The scrip opened at Rs. 1299.45 and has touched a high and low of Rs. 1332.05 and Rs. 1280.05 respectively. So far 4057 shares were traded on the counter. The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 1385.90 on 07-Nov-2022 and a 52 week low of Rs. 471.70 on 29-Nov-2021. Last one week high and low of the ...
Fredun Pharmaceuticals soars on bagging two contracts for Pharma and DC Granules
Fredun Pharmaceuticals soars on bagging two contracts for Pharma and DC Granules
Source: Accord Fintech
29/11/2022 12:44:46 PM
Buy Granules India Ltd For Target Rs. 415 - Religare Broking Granules India Ltd. (GRANULES) * Granules has been trading in a steady long term uptrend since 2012, after spending nearly 7 years in a prolonged consolidation phase after listing. * It usually witnesses time-wise correction after a strong directional up move. And, in line with past instances, it has been trading with a corrective bias for nearly two years, to digest the phenomenal surge from roughly 80 levels to a new record high of 433 levels. * It is currently hovering around the ...
Buy Granules India Ltd For Target Rs. 415 - Religare Broking
Buy Granules India Ltd For Target Rs. 415 - Religare Broking
Source: Religare Broking Ltd
17/10/2022 10:57:43 AM
Granules India jumps on getting ANDA approval for Loperamide Hydrochloride and Simethicone Tablets Granules India is currently trading at Rs. 306.85, up by 4.90 points or 1.62% from its previous closing of Rs. 301.95 on the BSE. The scrip opened at Rs. 301.80 and has touched a high and low of Rs. 307.65 and Rs. 301.80 respectively. So far 21178 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 362.25 on 14-Jan-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022. Last one week high and low of the scrip stood at ...
Granules India jumps on getting ANDA approval for Loperamide Hydrochloride and Simethicone Tablets
Granules India jumps on getting ANDA approval for Loperamide Hydrochloride and Simethicone Tablets
Source: Accord Fintech
30/08/2022 12:35:30 PM
Granules India surges on getting USFDA`s nod for Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets Granules India is currently trading at Rs. 310.65, up by 4.15 points or 1.35% from its previous closing of Rs. 306.50 on the BSE. The scrip opened at Rs. 310.00 and has touched a high and low of Rs. 312.95 and Rs. 308.00 respectively. So far 31785 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 362.25 on 14-Jan-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022. Last one week high and low of the scrip stood at ...
Granules India surges on getting USFDA`s nod for Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets
Granules India surges on getting USFDA`s nod for Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets
Source: Accord Fintech
26/08/2022 2:50:55 PM
Buy Granules India Ltd For Target Rs.370 - Motilal Oswal Ease of cost factors to drive a better outlook Exploring biotechnology as a new area of growth *  GRAN delivered a better than expected 1QFY23 performance, led by better operating leverage. It intends to add biotechnology as a new lever of growth. Likewise, it has acquired a small biotech company, which adds fermentation-based capabilities. * We raise our FY23/FY24 EPS estimate by 8% each, factoring in: a) reducing cost pressures in terms of raw materials as well as logistics co...
Buy Granules India Ltd For Target Rs.370 - Motilal Oswal
Buy Granules India Ltd For Target Rs.370 - Motilal Oswal
Source: Motilal Oswal Financial Services
12/08/2022 2:27:14 PM
Investment Idea - Buy Granules India Ltd For Target Rs.300 - Motilal Oswal Profitability revives sequentially; upgrade to BUY Multiple factors at play to improve business prospects going forward * Granules India (GRAN) delivered better-than-expected 4QFY22 performance at operational level. Better realization from paracetamol supported by new launches resulted in improved profitability on a QoQ basis. * We cut our EPS estimates by 3%/5% for FY23E/FY24E to factor in: a) increased price erosion in the base portfolio, b) opex towards MUPS/oncology block an...
Investment Idea - Buy Granules India Ltd For Target Rs.300 - Motilal Oswal
Investment Idea - Buy Granules India Ltd For Target Rs.300 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
30/05/2022 5:22:39 PM
Buy Granules India Limited Target Rs.360 - ICICI Direct APIs buoy revenues; margin headwinds persist… About the stock: Granules is a large-scale vertically integrated company that manufactures API, intermediates and finished dosages and has seven manufacturing facilities along with B2B & B2C marketing & distribution. Revenue mix FY21: Formulations – 52%, API (API+PFI) – 48% Top five products (Paracetamol, Ibuprofen, Metformin, Methocarbamol, Guaifenesin) contributed 84% to FY21 revenues Q3FY22 Results: Granul...
Buy Granules India Limited Target Rs.360 - ICICI Direct
Buy Granules India Limited Target Rs.360 - ICICI Direct
Source: ICICI Direct
12/04/2022 2:06:00 PM
Granules India trades higher as its arm gets ANDA approval for Bupropion Hydrochloride Extended-Release Tablets Granules India is currently trading at Rs. 324.95, up by 3.70 points or 1.15% from its previous closing of Rs. 321.25 on the BSE. The scrip opened at Rs. 321.00 and has touched a high and low of Rs. 326.90 and Rs. 321.00 respectively. So far 53199 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 404.50 on 04-Aug-2021 and a 52 week low of Rs. 285.80 on 15-Nov-2021. Last one week high and low of the scrip stood at ...
Granules India trades higher as its arm gets ANDA approval for Bupropion Hydrochloride Extended-Release Tablets
Granules India trades higher as its arm gets ANDA approval for Bupropion Hydrochloride Extended-Release Tablets
Source: Accord Fintech
3/02/2022 3:31:14 PM
Key News - Cars24, HCL Technologies Ltd, Kalpataru Power Transmission Ltd, Granules India Ltd, RBL Bank Ltd, IndiGo By ARETE Securities Key News Cars24 and Bajaj Finance partner to provide financing to used car buyers Cars24, a leading e-commerce platform for pre-owned vehicles has collaborated with Bajaj Finance Ltd., to lift the veil from used car financing and facilitate a quick, frictionless and streamlined shopping experience. This move follows a Series G funding round announced in December 2021 where the firm raised $400 million at a $3.3-billion valuation. While the consumer demand for pre-owned vehicles is skyro...
Key News - Cars24, HCL Technologies Ltd, Kalpataru Power Transmission Ltd, Granules India Ltd, RBL Bank Ltd, IndiGo By ARETE Securities
Key News - Cars24, HCL Technologies Ltd, Kalpataru Power Transmission Ltd, Granules India Ltd, RBL Bank Ltd, IndiGo By ARETE Securities
Source: ARETE Securities Ltd
31/12/2021 9:28:20 AM
Accumulate : Buy Granules India Ltd For Target Rs.349 - Geojit Financial Strong performance across segments.. Granules (Inc) is a leading generic player in the Indian Pharmaceutical industry, with 2/3rd of its revenue generated from North America and Europe. * Granules reported a subdued increase in revenue to Rs.888cr,up 3% YoY owing to increased sale of existing products and new launches especially in the Finished Dosage particles which has resulted in an increase in topline partially offset by loss of MEIS benefit. * For the quarter, EBITDA contra...
Accumulate : Buy Granules India Ltd For Target Rs.349 - Geojit Financial
Accumulate : Buy Granules India Ltd For Target Rs.349 - Geojit Financial
Source: Geojit Financial Services Ltd
18/11/2021 12:45:59 PM
Buy Granules India Ltd For Target Rs.440 - Motilal Oswal On track to build product pipeline as well as capacity Availability of key starting materials to improve over near term * Granules India (GRAN) delivered a better-than-expected 1QFY22 performance, led by better off-take in the Intermediates (PFI) and Finished Dosage (FD) segments. The impact of the sharp rise in key starting materials (KSM) for Paracetamol was offset by controlled opex, driving better-thanexpected profitability during the quarter. The improved availability of KSMs and n...
Buy Granules India Ltd For Target Rs.440 - Motilal Oswal
Buy Granules India Ltd For Target Rs.440 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
31/08/2021 10:21:43 AM
Buy Granules India Limited Target Rs.385 - Religare Broking Granules India Limited * Headquartered in Hyderabad, Granules India is one of the largest manufacturers of APIs like Ibuprofen, Metformin, Guaifenesin, Paracetamol and Methocarbamol for both the developed as well as emerging markets. Currently, it has eight manufacturing plants and presence in over 60 countries and has more than 250 customers. It operates in three verticals namely Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediates (PFI) and Finished Dosag...
Buy Granules India Limited Target Rs.385 - Religare Broking
Buy Granules India Limited Target Rs.385 - Religare Broking
Source: Religare Broking Ltd
19/07/2021 11:45:20 AM
Granules to provide 16 cr paracetamol tablets to Telangana Granules, a vertically-integrated pharmaceutical company headquartered in Hyderabad, on Wednesday announced it has pledged to provide the Telangana government paracetamol-500 mg tablets free of cost to fight the Covid-19 pandemic. The company will provide one crore tablets every week, starting from May 12, aggregating to 16 crore tablets worth Rs 8 crore over next four months. Granules India Executive Director Uma Devi Chigurupati said that they believe that this contribution will compl...
Granules to provide 16 cr paracetamol tablets to Telangana
Granules to provide 16 cr paracetamol tablets to Telangana
Source: IANS
13/05/2021 9:25:42 AM
Buy Granules India Ltd For Target Rs. 420 - Motilal Oswal Strong end to FY21; on track to develop product/add capacity Spike in KSM prices a hiccup in near-term earnings growth * GRAN delivered an in line performance in 4Q and posted its highest ever sales/EBITDA/PAT on an annual basis in FY21. This was largely led by strong traction in ingredients (PFIs) and formulations (FDs). While the company is on track to expand capacity/develop products, a sharp increase in prices of select key starting materials (KSM) may hinder its near-term performan...
Buy Granules India Ltd For Target Rs. 420 - Motilal Oswal
Buy Granules India Ltd For Target Rs. 420 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
12/05/2021 9:47:13 AM
Stock Picks - Wipro Ltd and Granules India​​​​​​​ Ltd By ICICI Direct Wipro Limited Buy Wipro Limited @ 513.00-515.00 CMP 513.10 TGT 524.50 SL 509.40   Granules India Limited Buy Granules India Limited @ 354.00-355.00 CMP 353.85 TGT 361.00 SL 351.20   To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/StaticData/Disclaimer.html   Views express by all participants are for information &...
Stock Picks - Wipro Ltd and Granules India​​​​​​​ Ltd By ICICI Direct
Stock Picks - Wipro Ltd and Granules India​​​​​​​ Ltd By ICICI Direct
Source: ICICI Direct
7/05/2021 11:17:58 AM
Stock Picks - Buy Granules Ltd For Target Rs. 363 - ICICI Direct Stock Picks Technical Observations * The stock has undergone healthy retracement over the past four months after witnessing relative outperformance during CY20. It is seen resuming its primary up trend after a higher base formation at the long term 52 week’s EMA (currently at | 304). It has acted as a major support for the stock in the entire up move since October 2019 as can be seen in the adjacent chart. Hence, offering a fresh entry opportunity with a favourable risk reward ...
Stock Picks - Buy Granules Ltd For Target Rs. 363 - ICICI Direct
Stock Picks - Buy Granules Ltd For Target Rs. 363 - ICICI Direct
Source: ICICI Direct
9/04/2021 12:33:36 PM
Buy Granules India Ltd For Target Rs. 380 - Religare Broking Religare Super Idea**   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer http://ex.religareonline.com/disclaimer SEBI Registration number is INZ000174330   Above views are of the author and not of the website kindly read disclaimer  
Buy Granules India Ltd For Target Rs. 380 - Religare Broking
Buy Granules India Ltd For Target Rs. 380 - Religare Broking
Source: Religare Broking Ltd
8/03/2021 10:35:35 AM
Buy Granules India Ltd For Target Rs.460 - Motilal Oswal Superior product mix drives profitability Expect healthy ANDA launches over the next 12-15 months * GRAN delivered an in line performance in 3QFY21. It sustained its strong earnings momentum led by Intermediates (PFI) and API segments. The delay in ANDA launches impacted the YoY growth rate for the Formulations segment. The company remains on track for capacity expansion at its Visakhapatnam and US sites to cater to growth in FY23-24. * We have tweaked our FY21E/FY22E/FY23E EPS estimat...
Buy Granules India Ltd For Target Rs.460 - Motilal Oswal
Buy Granules India Ltd For Target Rs.460 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
29/01/2021 12:08:32 PM